Video

EP. 1: An Introduction of the Speakers

Author(s):

Benjamin M. Brucker, MD,Eman A. Elkadry, MD

Urologist Benjamin Brucker, MD, urogynecologist Eman Elkadry, MD, and nurse practitioner Jenna Horton, NP introduce themselves, outline their credentials, and briefly describe the patients with overactive bladder (OAB) who they typically see in their clinical practice.

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

Sponsored by AbbVie US Medical Affairs

This content is intended for US/PR Healthcare Professionals.

The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.

Related Videos
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Related Content
First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI
April 24th 2025

First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI

Hannah Clarke
"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Gene therapy shows encouraging efficacy for overactive bladder
April 8th 2025

Gene therapy shows encouraging efficacy for overactive bladder

Hannah Clarke
At week 12, patients in the URO-902 cohorts demonstrated significantly greater improvements in daily microuritions vs placebo.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
FDA grants 510(k) clearance to Glean Urodynamics System
April 2nd 2025

FDA grants 510(k) clearance to Glean Urodynamics System

Hannah Clarke
"Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.
Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury
March 14th 2025

Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury

Hannah Clarke
The 52-week study plans to enroll 16 patients across 4 sites in the US.
© 2025 MJH Life Sciences

All rights reserved.